Literature DB >> 35312124

Whole-exome DNA sequencing in childhood anxiety disorders identifies rare de novo damaging coding variants.

Emily Olfson1,2, Eli R Lebowitz1, Grace Hommel1, Neha Pashankar1, Wendy K Silverman1, Thomas V Fernandez1,2.   

Abstract

BACKGROUND: Genetic factors contribute to the development of anxiety disorders, yet few risk genes have been previously identified. One genomic approach that has achieved success in identifying risk genes in related childhood neuropsychiatric conditions is investigations of de novo variants, which has yet to be leveraged in childhood anxiety disorders.
METHODS: We performed whole-exome DNA sequencing in 76 parent-child trios (68 trios after quality control) recruited from a childhood anxiety disorder clinic and compared rates of rare and ultra-rare de novo variants with 790 previously sequenced control trios (783 trios after quality control). We then explored overlap with risk genes for other neuropsychiatric conditions and enrichment in biologic pathways.
RESULTS: Rare and ultra-rare de novo likely gene disrupting and predicted damaging missense genetic variants are enriched in anxiety disorder probands compared with controls (rare variant rate ratio 1.97, 95% confidence interval [CI]: 1.11-3.34, p = .03; ultra-rare variant rate ratio 2.59, 95% CI: 1.35-4.70, p = .008). These de novo damaging variants occur in individuals with a variety of childhood anxiety disorders and impact genes that have been associated with other neuropsychiatric conditions. Exploratory network analyses reveal enrichment of deleterious variants in canonical biological pathways.
CONCLUSIONS: These findings provide a path for identifying risk genes and promising biologic pathways in childhood anxiety disorders by de novo genetic variant detection. Our results suggest the discovery potential of applying this approach in larger anxiety disorder cohorts to advance our understanding of the underlying biology of these common and debilitating conditions.
© 2022 Wiley Periodicals LLC.

Entities:  

Keywords:  anxiety disorders; biologic pathways; childhood; de novo; exome sequencing; genomics; rare variants

Mesh:

Substances:

Year:  2022        PMID: 35312124      PMCID: PMC9246845          DOI: 10.1002/da.23251

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   8.128


  39 in total

Review 1.  Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V.

Authors:  Katja Beesdo; Susanne Knappe; Daniel S Pine
Journal:  Psychiatr Clin North Am       Date:  2009-09

2.  B56δ-related protein phosphatase 2A dysfunction identified in patients with intellectual disability.

Authors:  Gunnar Houge; Dorien Haesen; Lisenka E L M Vissers; Sarju Mehta; Michael J Parker; Michael Wright; Julie Vogt; Shane McKee; John L Tolmie; Nuno Cordeiro; Tjitske Kleefstra; Marjolein H Willemsen; Margot R F Reijnders; Siren Berland; Eli Hayman; Eli Lahat; Eva H Brilstra; Koen L I van Gassen; Evelien Zonneveld-Huijssoon; Charlotte I de Bie; Alexander Hoischen; Evan E Eichler; Rita Holdhus; Vidar M Steen; Stein Ove Døskeland; Matthew E Hurles; David R FitzPatrick; Veerle Janssens
Journal:  J Clin Invest       Date:  2015-07-13       Impact factor: 14.808

3.  The Simons Simplex Collection: a resource for identification of autism genetic risk factors.

Authors:  Gerald D Fischbach; Catherine Lord
Journal:  Neuron       Date:  2010-10-21       Impact factor: 17.173

4.  External validation of comorbid patterns of anxiety disorders in children and adolescents.

Authors:  Ximena Franco; Lissette M Saavedra; Wendy K Silverman
Journal:  J Anxiety Disord       Date:  2006-11-13

Review 5.  Emerging drugs for the treatment of anxiety.

Authors:  James W Murrough; Sahab Yaqubi; Sehrish Sayed; Dennis S Charney
Journal:  Expert Opin Emerg Drugs       Date:  2015-06-01       Impact factor: 4.191

6.  Structure of genetic and environmental risk factors for dimensional representations of DSM-IV anxiety disorders.

Authors:  Kristian Tambs; Nikolai Czajkowsky; Espen Røysamb; Michael C Neale; Ted Reichborn-Kjennerud; Steven H Aggen; Jennifer R Harris; Ragnhild E Ørstavik; Kenneth S Kendler
Journal:  Br J Psychiatry       Date:  2009-10       Impact factor: 9.319

7.  Reproducible Genetic Risk Loci for Anxiety: Results From ∼200,000 Participants in the Million Veteran Program.

Authors:  Daniel F Levey; Joel Gelernter; Renato Polimanti; Hang Zhou; Zhongshan Cheng; Mihaela Aslan; Rachel Quaden; John Concato; Krishnan Radhakrishnan; Julien Bryois; Patrick F Sullivan; Murray B Stein
Journal:  Am J Psychiatry       Date:  2020-01-07       Impact factor: 18.112

8.  The phenotypic and genetic structure of depression and anxiety disorder symptoms in childhood, adolescence, and young adulthood.

Authors:  Monika A Waszczuk; Helena M S Zavos; Alice M Gregory; Thalia C Eley
Journal:  JAMA Psychiatry       Date:  2014-08       Impact factor: 21.596

9.  Exome sequencing in obsessive-compulsive disorder reveals a burden of rare damaging coding variants.

Authors:  Gerald Nestadt; David B Goldstein; Mathew Halvorsen; Jack Samuels; Ying Wang; Benjamin D Greenberg; Abby J Fyer; James T McCracken; Daniel A Geller; James A Knowles; Anthony W Zoghbi; Tess D Pottinger; Marco A Grados; Mark A Riddle; O Joseph Bienvenu; Paul S Nestadt; Janice Krasnow; Fernando S Goes; Brion Maher
Journal:  Nat Neurosci       Date:  2021-06-28       Impact factor: 24.884

10.  De Novo Sequence and Copy Number Variants Are Strongly Associated with Tourette Disorder and Implicate Cell Polarity in Pathogenesis.

Authors:  Sheng Wang; Jeffrey D Mandell; Yogesh Kumar; Nawei Sun; Montana T Morris; Juan Arbelaez; Cara Nasello; Shan Dong; Clif Duhn; Xin Zhao; Zhiyu Yang; Shanmukha S Padmanabhuni; Dongmei Yu; Robert A King; Andrea Dietrich; Najah Khalifa; Niklas Dahl; Alden Y Huang; Benjamin M Neale; Giovanni Coppola; Carol A Mathews; Jeremiah M Scharf; Thomas V Fernandez; Joseph D Buxbaum; Silvia De Rubeis; Dorothy E Grice; Jinchuan Xing; Gary A Heiman; Jay A Tischfield; Peristera Paschou; A Jeremy Willsey; Matthew W State
Journal:  Cell Rep       Date:  2018-09-25       Impact factor: 9.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.